(CNN Español) – The appearance of coronavirus variants is changing the way it combats the disease.
In this episode, Dr. Elmer Huerta has made recommendations that the United States Department of Medicine and Food should know about adapting tests, treatments, and vacancies to be effective against covid-19 variants.
You can watch this episode on Spotify or your podcast platform to learn or continue the transcript.
Hello, Elmer Soy Doctor Huerta and this is his dose of information about the new coronavirus. Information that we hope will help us to take care of our health and that of our families.
Here are some of the latest recommendations made by the Food and Drug Administration of the United States, the FDA, for the development of vacancies, diagnostic tests and treatments adapted to the new variants of SARS-19 CoV-2 .
Coronavirus variants: a preoccupation with the scientific community
As we have seen in various episodes, there is a lot of concern in the scientific community about the appearance of the new coronavirus variants.
More specifically, we are dealing with three of the variants identified of importance in public health:
- B.1.1.7, found in the United Kingdom;
- La B.1.351, discovered in South Africa,
- And the P.1, discovered in Brazil.
Preliminary studies have shown that some variants are more contagious than the original discovered in Wuhan, China.
The variants identified in South Africa and Brazil have the property of being resistant to the neutralizing activity of the anticursors directed against the original variant.
I have some deep implications:
- It is possible that a person has a covid-19 surface with the original variant can be re-infected with the resistant variants.
- The vacancies, diagnostic tests and treatments with monoclonal anticorrosive pierdan efficacy against the new variants. This possibility has been demonstrated with various vacancies of first generation.
It is for this reason that the FDA, in a communication on 22 February, called for the attention of pharmaceutical laboratories to adapt to the new variants of products such as vaccines, diagnostic tests and treatments with monoclonal antibodies.
What the FDA says about vacancies and coronavirus variants
In relation to vacancies, the FDA recommends that now -y with cargo discuss the details in the future- the new vacancies not related to pass through the large studies of phase 1, 2 and 3, if we demonstrate that they have the capacity to estimate the defense system in student centers that have no pre-emptive vacancies, as well as to study the effect of the new vacancies as the dose of refills in the pre-emptive vacancies.
Obviously, the study of these studies is that more serious series, tomarian less time that the clinical trials on a large scale and can be realized in a single eda group, extrapolating the results to other eda groups.
FDA officials confirm that the new strategy for new vacancies against covid-19 is based on the experience with the annual vacancies against vacancies.
Agreed with the Dra. Janet Woodcock, FDA’s Interinstitutional Commissioner, has experience with this, even though it is related to the new coronavirus, Cambian virus with time and the stationary flu change with much frequency.
Molecular samples and variants
In relation to the molecular tests that are used to identify the virus in patient secretions, the FDA states that it has identified some tests that are not sufficiently accurate to diagnose the new variants of this coronavirus.
This means that if you try to keep the virus in your respiratory tract, it will prove that the virus is not present, so it is a false negative result.
The FDA’s guideline proposes recommendations for which laboratories that develop the test are attentive to future genetic mutations of the virus and can easily adapt to the development of new exams.
What do you expect from the antidote treatment?
Finally, in relation to treatments with monoclonal antibodies, the FDA recommends that laboratories that modify the selection of their antibodies to adapt to the new variants.
The monoclonal antibodies, as described in the episodes of November 12 and February 7, are concentrated in the immunoglobulins of a single type that are specifically directed against the new coronavirus.
A summary, the theme of the SARS-CoV-2 variant appearance is not so unimportant, as described, it will radically change the development of vacancies, diagnostic tests and treatments against covid-19.
We are sure that science will adapt to the changes.
Mientras tanto, Independently of the variant that can be circulating in its community, we agree that:
- Avoid the infection using double mascarilla,
- Avoid people agglomerations,
- Geen organize ni acuda a social reunions con gente que no vive en su hogar,
- Y mantenga hygiene de manos y surface.
Do you have any questions about coronavirus?
Inquire by Twitter, we intend to respond to our upcoming episodes. You can meet @DrHuerta.
If you want this podcast to be useful, you can use it to find, qualify, in your favorite podcast application. Volveremos mañana, as well as making sure to subscribe to get the latest episode on his account.
And to get the most up-to-date information, you can always go to CNNEspanol.com. Thank you for your attention.
If you have any questions please Send to doctor Elmer Huerta via Twitter. También can also be directed to CNNE.com/coronaviruspodcast for all episodes of our podcast «Coronavirus: Reality vs. fiction ».